Becton Dickinson and Company
$ 154.85
-0.51%
23 Apr - close price
- Market Cap 44,049,662,000 USD
- Current Price $ 154.85
- High / Low $ 156.75 / 153.46
- Stock P/E 25.30
- Book Value 88.79
- EPS 6.12
- Next Earning Report 2026-05-07
- Dividend Per Share $4.17
- Dividend Yield 2.68 %
- Next Dividend Date -
- ROA 0.04 %
- ROE 0.07 %
- 52 Week High 186.16
- 52 Week Low 125.46
About
Becton, Dickinson and Company, also known as BD, is an American multinational medical technology company that manufactures and sells medical devices, instrument systems, and reagents. BD also provides consulting and analytics services in certain geographies.
Analyst Target Price
$191.46
Quarterly Earnings
| Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | Mar 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2026-02-03 | 2025-11-06 | 2025-08-07 | 2025-05-01 | 2025-02-05 | 2024-11-07 | 2024-08-01 | 2024-05-02 | 2024-02-01 | 2023-11-09 | 2023-08-03 | 2023-05-04 |
| Reported EPS | 2.91 | 3.96 | 3.68 | 3.35 | 3.43 | 3.81 | 3.5 | 3.17 | 2.68 | 3.42 | 2.96 | 2.86 |
| Estimated EPS | 3.24 | 3.92 | 3.4 | 3.28 | 2.99 | 3.77 | 3.31 | 2.97 | 2.4 | 3.43 | 2.91 | 2.74 |
| Surprise | -0.33 | 0.04 | 0.28 | 0.07 | 0.44 | 0.04 | 0.19 | 0.2 | 0.28 | -0.01 | 0.05 | 0.12 |
| Surprise Percentage | -10.1852% | 1.0204% | 8.2353% | 2.1341% | 14.7157% | 1.061% | 5.7402% | 6.734% | 11.6667% | -0.2915% | 1.7182% | 4.3796% |
Next Quarterly Earnings
| Mar 2026 | |
|---|---|
| Reported Date | 2026-05-07 |
| Fiscal Date Ending | 2026-03-31 |
| Estimated EPS | 2.77 |
| Currency | USD |
Previous Dividend Records
| Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Payment Date | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 | 2024-06-28 | 2024-03-29 | 2023-12-29 |
| Amount | $1.05 | $1.05 | $1.04 | $1.04 | $1.04 | $1.04 | $0.95 | $0.95 | $0.95 | $0.95 |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: BDX
2026-04-22 23:15:08
Becton Dickinson (BDX) has experienced prolonged share price weakness, with its stock broadly flat over the last month and down significantly year-to-date and over three and five years. Despite this, a Discounted Cash Flow (DCF) analysis suggests the company is undervalued by 27.5%, with an estimated intrinsic value of $214.69 per share compared to its current price of approximately $155.65. The company's P/E ratio of 25.2x also sits below its calculated "Fair Ratio" of 29.1x, further indicating a potential undervaluation relative to its earnings profile and industry peers.
2026-04-22 23:07:08
Becton Dickinson (BDX) has experienced prolonged share price weakness, with a modest 0.2% increase over the past year and losses over three and five years. Despite this, a Discounted Cash Flow (DCF) analysis suggests the stock is undervalued by 27.5%, with an estimated intrinsic value of $214.69 per share compared to its current price of $155.65. The company's P/E ratio of 25.2x is also below its calculated "Fair Ratio" of 29.1x, further indicating undervaluation based on its earnings profile.
2026-04-22 00:38:32
West Pharmaceutical Services (NYSE:WST) is gaining investor attention due to its key role in the expanding global wearable injectors market, a trend driven by the rise of chronic disease treatment at home. The company's stock has seen significant short-term growth, with analysts projecting positive earnings and revenue growth. However, investors should consider potential execution risks and competitive pressures, while also recognizing the long-term benefits of West's position in this critical healthcare segment.
2026-04-22 00:37:39
West Pharmaceutical Services is gaining renewed investor attention due to its central role in the expanding global wearable injectors market, driven by increased home-based chronic disease treatment and connected drug delivery platforms. The company's stock has seen significant short-term growth, reflecting investor interest in its potential to capitalize on this trend, though risks like execution capacity and competitive pressures remain. Analysts project positive near-term earnings and revenue growth, partly supported by a narrative focusing on higher-value drug delivery components.
2026-04-21 16:51:00
Becton Dickinson & Co. (BDX) stock fell 1.23% to $156.69 on Tuesday, underperforming the broader market as the S&P 500 Index and Dow Jones Industrial Average also declined. This dip broke a two-day winning streak for the company's shares.
2026-04-21 11:47:26
Worldwide Market Reports (WMR) has published an in-depth study on the "Automated Cell Culture Market Size and Forecast 2026-2033." The report provides a data-driven analysis of historical trends and future projections for the global market, highlighting growth drivers, opportunities, risks, and challenges. It includes SWOT analysis, Porter's Five Forces framework, regional performance, and profiles of key industry players such as Thermo Fisher Scientific and Merck KGaA.
